Unknown

Dataset Information

0

A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis.


ABSTRACT: Diarrhoeal disease is responsible for 8.6% of global child mortality. Recent epidemiological studies found the protozoan parasite Cryptosporidium to be a leading cause of paediatric diarrhoea, with particularly grave impact on infants and immunocompromised individuals. There is neither a vaccine nor an effective treatment. Here we establish a drug discovery process built on scalable phenotypic assays and mouse models that take advantage of transgenic parasites. Screening a library of compounds with anti-parasitic activity, we identify pyrazolopyridines as inhibitors of Cryptosporidium parvum and Cryptosporidium hominis. Oral treatment with the pyrazolopyridine KDU731 results in a potent reduction in intestinal infection of immunocompromised mice. Treatment also leads to rapid resolution of diarrhoea and dehydration in neonatal calves, a clinical model of cryptosporidiosis that closely resembles human infection. Our results suggest that the Cryptosporidium lipid kinase PI(4)K (phosphatidylinositol-4-OH kinase) is a target for pyrazolopyridines and that KDU731 warrants further preclinical evaluation as a drug candidate for the treatment of cryptosporidiosis.

SUBMITTER: Manjunatha UH 

PROVIDER: S-EPMC5473467 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6597546 | biostudies-literature
| S-EPMC7558405 | biostudies-literature
| S-EPMC10425216 | biostudies-literature
| S-EPMC3165992 | biostudies-literature
| S-EPMC3697674 | biostudies-literature
| S-EPMC4254006 | biostudies-literature
| S-EPMC6256802 | biostudies-literature
| S-EPMC3536213 | biostudies-literature
| S-EPMC85515 | biostudies-literature
| S-EPMC2732472 | biostudies-literature